Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical has called its next annual general meeting for 17 June 2025 in hybrid format, combining an in-person session in Hong Kong with an online e-voting platform to facilitate broader shareholder participation. The agenda includes receiving the 2025 audited results, approving a final dividend, re-electing directors, re-appointing Ernst & Young as auditor, and granting the board authority to issue up to 20% of the company’s share capital, measures that collectively shape governance, capital-raising flexibility and shareholder returns for the coming year.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a Hong Kong–listed pharmaceutical company engaged in the research, development and commercialization of biopharmaceutical and chemical medicines. The group focuses on the healthcare sector, providing a range of therapeutic products to the mainland China and broader Asian markets, and is listed on the Main Board of the Hong Kong Stock Exchange under stock code 1177.
Average Trading Volume: 71,429,429
Technical Sentiment Signal: Buy
Current Market Cap: HK$99B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.